Table 2.
Prescriptions and laboratory data before and after procedure
| Parameters | Total (n = 30) | BP-EES (n = 15) | DP-EES (n = 15) | P-value |
|---|---|---|---|---|
| Prescriptions | ||||
| DAPT | 23 (76.6) | 11 (73.3) | 12 (80.0) | 1.000 |
| Duration of DAPT, days | 354 (319–407) | 364 (340–407) | 343 (259–410) | 0.278 |
| Cilostazol | 1 (3.3) | 0 (0) | 1 (6.7) | 1.000 |
| Aspirin | 23 (76.7) | 11 (73.3) | 12 (80.0) | 1.000 |
| Clopidogrel | 19 (63.3) | 9 (60.0) | 10 (66.7) | 1.000 |
| Prasugrel | 10 (33.3) | 6 (40.0) | 4 (26.7) | 0.700 |
| Oral Anticoagulants | 6 (20.0) | 3 (20.0) | 3 (20.0) | 1.000 |
| ACE-i/ARB | 18 (60.0) | 9 (60.0) | 9 (60.0) | 1.000 |
| β-blocker | 13 (43.3) | 7 (46.7) | 6 (40.0) | 1.000 |
| Statin | 28 (93.3) | 14 (93.3) | 14 (93.3) | 1.000 |
| Laboratory data | ||||
| Pre-procedure | ||||
| eGFR, mL/min per 1.73 m2 | 63.2 (51.2–73.3) | 62.4 (52.8–75.9) | 64.0 (50.3–72.9) | 0.624 |
| Hs-CRP, mg/dL | 0.11 (0.03–0.29) | 0.17 (0.07–0.29) | 0.06 (0.03–0.21) | 0.253 |
| TG, mg/dL | 98 (73–119) | 71 (62–150) | 108 (97–131) | 0.006 |
| T.Cho, mg/dL | 147 (126–164) | 140 (125–161) | 150 (130–169) | 0.372 |
| HDL-C, mg/dL | 47 (34–58) | 49 (36–56) | 44 (34–71) | 0.983 |
| LDL-C, mg/dL | 77 (67–99) | 77 (69–95) | 78 (68–99) | 0.930 |
| HbA1c, % | 6.3 (5.9–6.7) | 6.0 (5.8–6.4) | 6.4 (6.1–6.9) | 0.084 |
| BS, mg/dL | 100 (92–119) | 94 (86–103) | 113 (98–131) | 0.044 |
| CK, U/L | 95 (64–165) | 92 (72–154) | 97 (58–180) | 0.934 |
| CK-MB, U/L | 8 (7–11) | 8 (7–13) | 9 (8–11) | 0.834 |
| Hs-TnT, ng/mL | 0.015 (0.008–0.024) | 0.016 (0.009–0.021) | 0.014 (0.009–0.050) | 0.868 |
| BNP, pg/mL | 66.7 (17.0–114.8) | 82.1 (38.8–110.0) | 26.6 (15.2–103.9) | 0.123 |
| Post-procedure | ||||
| eGFR, mL/min per 1.73 m2 | 60.6 (52.0–74.9) | 57.4 (47.2–75.6) | 61.8 (55.7–72.6) | 0.595 |
| CK, U/L | 118 (87–157) | 119 (91–143) | 103 (85–172) | 1.000 |
| CK-MB, U/L | 10 (7–15) | 12 (8–15) | 10 (7–14) | 0.662 |
| Hs-TnT, ng/mL | 0.103 (0.070–0.187) | 0.137 (0.085–0.190) | 0.098 (0.057–0.142) | 0.266 |
Data presented as n (%) or interquartile range (25%–75%)
DAPT dual anti-platelet therapy, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, eGFR estimated glomerular filtration rate, Hs-CRP high sensitivity C-reactive protein, TG triglyceride, T.Cho total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HbA1c hemoglobin A1c, BS blood sugar, CK creatine kinase, CK-MB creatine kinase MB, Hs-TnT high-sensitivity troponin T, BNP brain natriuretic peptide